Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics strengthens the business with two key appointments

The drug developer has drafted in a new director as well as recruiting a head of clinical development
boardroom table
There will be a new face around the boardroom table

Silence Therapeutics PLC (LON:SLN) has made two key appointments that will respectively strengthen the board and the business. 

Dave Lemus, currently chief operating officer and chief financial officer of Proteros  Biostructures, has been appointed an independent director.  

READ: Silence Therapeutics on track to be a clinical stage company by year-end

Chairman Annalisa Jenkins said: "Dave has joined at a pivotal time for the company. His successful track record and proven leadership in building and managing high performance management teams will strengthen our capabilities as we continue to maximise the potential of our GalNAc-based SRNi platform."

Meanwhile, Richard Jenkins comes on board as head of clinical development, replacing chief scientific officer Torsten Hoffmann who is leaving Silence for personal reasons.

Jenkins, who has worked for Takeda and GlaxoSmithKline, will oversee the development of the company's main drug candidate, a compound for iron overload, as it progresses towards clinical trials. He will report directly to chairman Jenkins.

 

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use